Question 1

What is an in vivo efficacy study?

Accepted Answer

An in vivo efficacy study evaluates the therapeutic activity of a drug candidate in animal models before clinical trials. These studies help researchers assess anti-tumor activity, pharmacological effects, mechanism of action, dose response, and overall proof-of-concept in a living biological system. In vivo efficacy testing is a critical step for candidate selection, IND-enabling studies, and reducing development risk before human trials.

Question 2

Why are in vivo efficacy studies important in drug development?

Accepted Answer

While in vitro experiments provide valuable early-stage data, they cannot fully replicate the complexity of human biology. In vivo efficacy studies allow researchers to evaluate therapeutic performance within a complete biological system, including tumor growth, immune responses, pharmacodynamics, and disease progression. These studies provide critical evidence to support candidate advancement and clinical trial planning.

Question 3

How do I select the right animal model for an in vivo efficacy study?

Accepted Answer

Selecting an appropriate animal model depends on the therapeutic modality, target biology, mechanism of action, and study objectives. Typical model selection includes: syngeneic models for immuno-oncology and immune-response evaluation; CDX (Cell-Derived Xenograft) models for assessing tumor growth inhibition of targeted therapies and antibodies; humanized mouse models for T cell engagers, bispecific antibodies, CAR-T therapies, and immune checkpoint therapies; transgenic models for investigating target biology and disease mechanisms; and PDX models when patient-derived tumor characteristics are required. ProBio's scientific team helps identify the most predictive model based on indication and therapeutic modality.

Question 4

How is the in vivo efficacy of bispecific antibodies evaluated?

Accepted Answer

The most suitable model depends on the bispecific antibody's mechanism of action. Immune cell-engaging bispecific antibodies (such as CD3 T-cell engagers) are typically evaluated using PBMC-humanized or HSC-humanized mouse models; bispecific antibodies targeting two signaling pathways may be studied in humanized, transgenic, or xenograft models; and bispecific antibodies targeting multiple tumor antigens can be assessed using transgenic, CDX, or PDX models. Humanized mouse models are often preferred because they enable evaluation of human immune cell activation and anti-tumor responses in vivo.

Question 5

Which biologics can be evaluated using ProBio's in vivo efficacy platform?

Accepted Answer

ProBio supports efficacy evaluation for diverse biologics modalities, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), CAR-T and NK cell therapies, gene therapies, vaccines, T-cell engagers (TCEs), and recombinant proteins. Our scientists recommend the most suitable efficacy model and study design based on target biology, indication, and therapeutic mechanism.

Question 6

What in vivo efficacy services does ProBio provide?

Accepted Answer

ProBio offers comprehensive in vivo efficacy evaluation services through an integrated pharmacology platform, including syngeneic tumor models, CDX models, PBMC-humanized and HSC-humanized models, orthotopic and metastatic tumor models, autoimmune disease models, metabolic disease models, customized disease model development, and study design and data analysis support. With more than 200 tumor cell lines and an extensive portfolio of oncology and non-oncology disease models, ProBio helps accelerate candidate selection and preclinical decision-making. More details can be found in the tables on the page.

Question 7

What is the difference between syngeneic, CDX, and humanized mouse models?

Accepted Answer

Syngeneic models use mouse-derived tumors in immunocompetent mice and are ideal for studying immune responses. CDX models use human cancer cell lines implanted into immunodeficient mice and are widely used for tumor efficacy assessment. Humanized mouse models contain human immune cells and are particularly valuable for evaluating immunotherapies, bispecific antibodies, and cell therapies that depend on human immune interactions.

In Vivo Efficacy Study

In Vivo Models and Efficacy Evaluation Services for Drug Development

Extensive Ready-to-use Models

IND-Enabling Infrastructure

One-Stop Solution

In Vivo Efficacy Studies Using Advanced Tumor and Disease Models

Extensive Models

Diverse Tumor Cell Lines

Broad Disease Models

Case Study

CD3 Bispecific Antibody Demonstrates Strong Anti-Tumor Activity in Humanized SHP77 Mouse Model.

Resources

Biologics Discovery Services Brochure

In Vivo Pharmacology

How to Design and Evaluate Bispecific Antibodies (BsAbs)?

Powerdoma™: An Upgraded Hybridoma Platform

Advance Your Drug Candidate with Confidence

Related Services

Antibody Lead Optimization

TCR Engineering Services

In Vitro Bioassay

Developability Assessment

Antibody Humanization

In Vivo Toxicology

Frequently Asked Questions